Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease
Published December 2024
Moses J, Adler J, Saeed SA, Firestine AM, Galanko JA, Ammoury RF, Bass DM, Bass JA, Bastidas M, Benkov KJ, Bousvaros A, Cabrera JM, Chun KY, Dorsey JM, Ebach DR, Gulati AS, Herfarth HH, Ivanova A, Jester TW, Kaplan JL, Kusek ME, Leibowitz IH, Linville TM, Margolis PA, Minar P, Molle-Rios Z, Niklinska-Schirtz BJ, Olano KK, Osaba L, Palomo PJ, Pashankar DS, Pitch L, Samson CM, Sandberg KC, Steiner SJ, Strople JA, Sullivan JS, Tung J, Wali P, Wohl DA, Zikry M, Boyle BM, Kappelman MD
Higher drug levels and combination therapy with low-dose oral methotrexate (LD-MTX) may reduce anti-tumor necrosis factor (TNF) treatment failure in pediatric Crohn's disease. We sought to (1) evaluate whether combination therapy with LD-MTX was associated with higher anti-TNF levels, (2) evaluate associations between anti-TNF levels and subsequent treatment failure, and (3) explore the effect of combination therapy on maintenance of remission among patients with therapeutic drug levels (>5 µg/mL for infliximab and >7.5 µg/mL for adalimumab).
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease
Published October 2024
Adler J, Galanko JA, Ammoury R, Benkov KJ, Bousvaros A, Boyle B, Cabrera JM, Chun KY, Dorsey J, Ebach DR, Firestine AM, Gulati AS, Herfarth HH, Jester TW, Kaplan JL, Leibowitz I, Linville TM, Margolis PA, Minar P, Molle-Rios Z, Moses J, Olano K, Pashankar DS, Pitch L, Saeed SA, Samson CM, Sandberg K, Steiner SJ, Strople JA, Sullivan JS, Wali PD, Kappelman MD
HLA DQA1*05 has been associated with the development of anti-drug antibodies (ADA) to tumor necrosis factor antagonists (anti-TNF) and treatment failure among adults with Crohn's disease (CD). However, findings from other studies have been inconsistent with limited pediatric data.
The association between erythema nodosum and pyoderma gangrenosum and pediatric inflammatory bowel disease
Published September 2024
Yousif ML, Ritchey A, Mirea L, Patel AS, Price H, O'Haver J, Montoya L, Gonzalez-Llanos L, Smith J, Zeblisky K, Pasternak B.
The objectives of this study is to estimate rates and identify factors associated with erythema nodosum (EN) and pyoderma gangrenosum (PG) in pediatric patients with inflammatory bowel disease (IBD).
Travel Time to Treating Center is Associated With Diagnostic Delay in Pediatric Inflammatory Bowel Disease
Published August 2024
McLaughlin JF, Linville T, Jester TW, Marciano TA, Lazare F, Dotson JL, Samson C, Niklinska-Schirtz B, Cabrera J, Leibowtiz I, Batra S, Ammoury R, Strople JA, Saeed S, Sandberg KC, Tung J, Verstraete SG, Cox RF, Na S, Steiner SJ, Ali SA, Israel EJ, Dorsey J, Adler J, Rekhtman Y, Egberg MD, Waduge ER, Savas J, Brensinger CM, Lewis JD, Kappelman MD.
Delayed diagnosis of inflammatory bowel disease (IBD) leads to prolonged symptoms and worse long-term outcomes. We sought to evaluate whether race, ethnicity, disease type, and social factors are associated with delayed diagnosis of pediatric IBD.
We performed a cross-sectional study of newly diagnosed pediatric patients with IBD at 22 United States sites from 2019 to 2022. Parents/guardians reported race, ethnicity, time between symptom onset and diagnosis, and other social determinants of health. Through bivariate and multivariable analyses using generalized estimating equations, we evaluated associations between these factors and diagnosis time defined as ≤60 days, 61 to 180 days, 181 to 365 days, and >365 days.
Characterization of Biologic Discontinuation Among Pediatric Patients with Crohn’s Disease
Published May 2024
Ali S, Pasternak B, Moses J, Suskind DL, Samson C, Kaplan J, Creps J, Manning L, Baker M, Singer D, Paterl P, Trombler B, Anandakrishnan A, Khorrami C, Feldman M, McGoldrick M, Adler J.
Biologic therapies may effectively treat Crohn’s disease (CD), and pediatric patients who discontinue multiple biologics risk exhausting treatment options. The frequency and context of biologic discontinuation has not been well characterized. We aimed to determine patterns of biologic use, discontinuation, and evaluation in pediatric patients with CD.
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease
Published March 2024
Dawn R Ebach, Traci W Jester, Joseph A Galanko, Ann M Firestine, Rana Ammoury, Jose Cabrera, Julie Bass, Phillip Minar, Kelly Olano, Peter Margolis, Kelly Sandberg, Tiffany M Linville, Jess Kaplan, Lisa Pitch, Steven J Steiner, Dorsey Bass, Jonathan Moses, Jeremy Adler, Ajay S Gulati, Prateek Wali, Dinesh Pashankar, Anastasia Ivanova, Hans Herfarth, David A Wohl, Keith J Benkov, Jennifer Strople, Jillian Sullivan, Jeanne Tung, Zorela Molle-Rios, Shehzad A Saeed, Athos Bousvaros, Michael D Kappelman
Obesity is common among patients with pediatric Crohn's disease (PCD). Some adult studies suggest obese patients respond less well to anti-tumor necrosis factor (TNF) treatment. This study sought compares anti-TNF response and anti-TNF levels between pediatric patients with normal and high body mass index (BMI).
Real-world effectiveness of ustekinumab and vedolizumab in TNF-exposed pediatric patients with ulcerative colitis
Published March 2024
Patel PV, Zhang A, Bhasuran B, Ravindranath VG, Heyman MB, Verstraete SG, Butte AJ, Rosen MJ, Rudrapatna VA;
Vedolizumab (VDZ) and ustekinumab (UST) are second-line treatments in pediatric patients with ulcerative colitis (UC) refractory to antitumor necrosis factor (anti-TNF) therapy. Pediatric studies comparing the effectiveness of these medications are lacking. Using a registry from ImproveCareNow (ICN), a global research network in pediatric inflammatory bowel disease, we compared the effectiveness of UST and VDZ in anti-TNF refractory UC.
Is it “all in the bag?” Multidisciplinary perspectives on ostomy surgery in pediatric IBD across the ImproveCareNow network
Published January 2024
Jennie G. David, Jennifer Dotson, Laura Mackner
Pediatric inflammatory bowel disease (IBD) is a chronic illness with various treatments, including ostomy surgery. Ostomy‐related medical decision‐making (MDM) is complex for multidisciplinary healthcare professionals (HCPs). This study sought to understand national multidisciplinary HCPs' perceptions about pediatric IBD ostomy surgery in the United States.
Diagnosis change in pediatric inflammatory bowel disease
Published January 2024
Duarte H, Stolfi A, McCall C, Saeed S, Sandberg K.
This study aims to characterize pediatric inflammatory bowel disease (IBD) patients who change diagnosis and describe the characteristics of that change.